000661 长春高新
已收盘 12-29 15:00:00
资讯
新帖
简况
长春高新:销售费用增长因新产品推广
证券之星 · 12-26
长春高新:销售费用增长因新产品推广
长春高新:优先推动产品在国内销售推广
证券之星 · 12-26
长春高新:优先推动产品在国内销售推广
长春高新(000661.SZ):金赛药业GenSci141软膏注册临床试验申请获得受理
智通财经 · 12-26
长春高新(000661.SZ):金赛药业GenSci141软膏注册临床试验申请获得受理
光鲜下的另一面,BD交易后股价不涨反跌成常态?专家:短期热度降低不是坏事
时代周报 · 12-25
光鲜下的另一面,BD交易后股价不涨反跌成常态?专家:短期热度降低不是坏事
长春高新(000661)披露子公司GenSci145片临床试验申请获受理,12月24日股价上涨0.43%
证券之星 · 12-24
长春高新(000661)披露子公司GenSci145片临床试验申请获受理,12月24日股价上涨0.43%
长春高新:无法掌握具体适应症占比的准确信息
证券之星 · 12-23
长春高新:无法掌握具体适应症占比的准确信息
长春高新表示其子公司预计将收到1.2亿美元的预付款和早期里程碑付款
美股速递 · 12-15
长春高新表示其子公司预计将收到1.2亿美元的预付款和早期里程碑付款
长春高新宣布子公司与Yarrow Bioscience签署Gensci098注射剂项目许可协议
美股速递 · 12-15
长春高新宣布子公司与Yarrow Bioscience签署Gensci098注射剂项目许可协议
长春高新最新公告:下属公司签署GenSci098注射液项目独家许可协议可至多获得13.65亿美元里程碑付款
证券之星 · 12-15
长春高新最新公告:下属公司签署GenSci098注射液项目独家许可协议可至多获得13.65亿美元里程碑付款
长春高新:长效生长激素规格及医保价格说明
证券之星 · 12-15
长春高新:长效生长激素规格及医保价格说明
长春高新:系统性推进市值管理
证券之星 · 12-15
长春高新:系统性推进市值管理
长春高新(000661.SZ)子公司两款药品新纳入国家医保目录
智通财经 · 12-08
长春高新(000661.SZ)子公司两款药品新纳入国家医保目录
长春高新:已回购股份将用于员工持股或股权激励
证券之星 · 12-04
长春高新:已回购股份将用于员工持股或股权激励
长春高新:推进多元化转型升级
证券之星 · 12-03
长春高新:推进多元化转型升级
长春高新:提升资产使用效率及项目竞争力
证券之星 · 12-03
长春高新:提升资产使用效率及项目竞争力
长春高新:截至9月30日股东人数为104,055
证券之星 · 12-03
长春高新:截至9月30日股东人数为104,055
长春高新(000661.SZ):GenSci142胶囊境内生产药品注册临床试验申请获批准
智通财经 · 11-27
长春高新(000661.SZ):GenSci142胶囊境内生产药品注册临床试验申请获批准
长春高新:相关工作具有不确定性
证券之星 · 11-24
长春高新:相关工作具有不确定性
长春高新:未发现生长激素市场份额下降的科学合理性
证券之星 · 11-24
长春高新:未发现生长激素市场份额下降的科学合理性
长春高新:成功推出10余种新药产品
证券之星 · 11-24
长春高新:成功推出10余种新药产品
加载更多
公司概况
公司名称:
长春高新技术产业(集团)股份有限公司
所属行业:
医药制造业
上市日期:
1996-12-18
主营业务:
长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售,辅以房地产开发等业务。公司的主要产品是注射用人生长激素、重组人生长激素注射液、聚乙二醇重组人生长激素注射液、营养保健产品、体重控制产品、电子注射笔、骨龄及生长发育检测设备、赛优姿系列产品、盐酸托莫西汀胶囊、注射用重组人促卵泡激素、醋酸曲普瑞林注射液、利丙双卡因乳膏、醋酸甲地孕酮口服混悬液、口腔凝胶。
发行价格:
8.80
{"stockData":{"symbol":"000661","market":"SZ","secType":"STK","nameCN":"长春高新","latestPrice":93.23,"timestamp":1766991837000,"preClose":94.37,"halted":0,"volume":5322399,"delay":0,"changeRate":-0.0121,"floatShares":400000000,"shares":408000000,"eps":2.351,"marketStatus":"已收盘","change":-1.14,"latestTime":"12-29 15:00:00","open":94.37,"high":94.37,"low":92.97,"amount":498000000,"amplitude":0.0148,"askPrice":93.23,"askSize":61,"bidPrice":93.22,"bidSize":552,"shortable":0,"etf":0,"ttmEps":2.351,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767058200000},"marketStatusCode":5,"adr":0,"adjPreClose":94.37,"symbolType":"stock","openAndCloseTimeList":[[1766971800000,1766979000000],[1766984400000,1766991600000]],"highLimit":103.81,"lowLimit":84.93,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":407937529,"isCdr":false,"pbRate":1.67,"roa":"--","peRate":39.655466,"roe":"5.03%","epsLYR":6.42,"committee":0.512605,"marketValue":38032000000,"turnoverRate":0.0133,"status":1,"floatMarketCap":37256000000},"requestUrl":"/m/hq/s/000661","defaultTab":"news","newsList":[{"id":"2594260943","title":"长春高新:销售费用增长因新产品推广","url":"https://stock-news.laohu8.com/highlight/detail?id=2594260943","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594260943?lang=zh_cn&edition=full","pubTime":"2025-12-26 17:30","pubTimestamp":1766741433,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新12月26日在投资者关系平台上答复投资者关心的问题。投资者提问:2025年上半年销售费用同比增长超30%,但净利润同比下滑25%,请说明销售费用的主要开支项及与营收增长不匹配的原因。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600025214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0028","BK0188","BK0057","BK0075","BK0046","BK0239"],"gpt_icon":0},{"id":"2594267006","title":"长春高新:优先推动产品在国内销售推广","url":"https://stock-news.laohu8.com/highlight/detail?id=2594267006","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594267006?lang=zh_cn&edition=full","pubTime":"2025-12-26 17:12","pubTimestamp":1766740342,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新12月26日在投资者关系平台上答复投资者关心的问题。为什么贵公司不再美国FDA申请做金蓓欣临床试验?因此,目前公司基于相关产品在国内市场中的良好潜力,优先推动其在国内的销售推广工作,谢谢!","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600024383.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0188","BK0046","BK0075","000661","BK0239","BK0028"],"gpt_icon":0},{"id":"2594826291","title":"长春高新(000661.SZ):金赛药业GenSci141软膏注册临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2594826291","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594826291?lang=zh_cn&edition=full","pubTime":"2025-12-26 16:04","pubTimestamp":1766736287,"startTime":"0","endTime":"0","summary":"智通财经APP讯,长春高新(000661.SZ)发布公告,近日,公司子公司——长春金赛药业有限责任公司(以下简称“金赛药业”)收到国家药品监督管理局核准签发的《受理通知书》,金赛药业GenSci141软膏注册临床试验申请获得受理。据悉,GenSci141软膏是金赛药业研发的一款双氢睾酮软膏,主要以旁分泌的方式在靶组织内发挥作用,属于化学药品2.2和2.4类。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386017.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"长春高新(000661.SZ):金赛药业GenSci141软膏注册临床试验申请获得受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0075","000661","BK0188","BK0046","BK0057","BK0239"],"gpt_icon":0},{"id":"2594287939","title":"光鲜下的另一面,BD交易后股价不涨反跌成常态?专家:短期热度降低不是坏事","url":"https://stock-news.laohu8.com/highlight/detail?id=2594287939","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594287939?lang=zh_cn&edition=full","pubTime":"2025-12-25 14:21","pubTimestamp":1766643688,"startTime":"0","endTime":"0","summary":"今年创新药企业频繁宣布BD交易,但从三季度以来,原本利好的消息却不被二级市场买账。最近一周,BD交易再掀一个小高潮。12月22日,先声药业(02096.HK)宣布其附属公司江苏再明与Ipsen于12月19日签订独家授权许可协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512253601825588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1593","BK0196","03692","02096","BK0060","688062","603087","BK0183","BK1161","LU2580892862.HKD","LU0405327494.USD","LU2097828805.USD","BK0028","LU2097828557.USD","LU1328615791.USD","01530","LU1146622755.USD","688336","09995","688428","01167","LU2488822045.USD","LU2097828714.EUR","600276","LU0405327148.USD","BK1589","002755","LU1781817850.SGD","000661","LU1997245177.USD","LU1997245094.SGD","LU1064131003.USD","LU2097828474.EUR","BK0057","BK0012","BK1574","LU2097828631.EUR","06978","LU2148510915.USD","02509","BK0239","02142","LU1997244956.HKD","BK0188","LU0502904849.HKD","688331","LU1064130708.USD","LU2495084118.USD","LU1969619763.USD","01801"],"gpt_icon":0},{"id":"2593747051","title":"长春高新(000661)披露子公司GenSci145片临床试验申请获受理,12月24日股价上涨0.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593747051","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593747051?lang=zh_cn&edition=full","pubTime":"2025-12-24 22:10","pubTimestamp":1766585411,"startTime":"0","endTime":"0","summary":"截至2025年12月24日收盘,长春高新报收于94.09元,较前一交易日上涨0.43%,最新总市值为383.83亿元。该股当日开盘93.59元,最高94.17元,最低93.2元,成交额达3.6亿元,换手率为0.96%。公司近日发布公告称,子公司金赛药业提交的GenSci145片境内生产药品注册临床试验申请已获国家药品监督管理局受理。该药品适应症为携带PIK3CA突变的局部晚期或转移性实体瘤。GenSci145片为新型突变选择性PI3Kα抑制剂,临床前研究显示其具有较强的选择性抑制活性、有效性及良好的安全性特征。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400040246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91272","BK0188","BK0057","000661","BK0046","BK0075","BK0028","BK0239"],"gpt_icon":0},{"id":"2593493159","title":"长春高新:无法掌握具体适应症占比的准确信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2593493159","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593493159?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:54","pubTimestamp":1766480094,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新12月23日在投资者关系平台上答复投资者关心的问题。导致其他适应症同价,能否告知其他适应症占比多少?公司有无掌握其他在研在售产品,目前竞争对手上市阶段,有无研判竞品上市后销售策略?针对竞品公司的竞争,公司管理层有无考虑放弃那些多适应症性价比不高的研发投入!","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300026240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0057","BK0046","000661","BK0188","91272","BK0075"],"gpt_icon":0},{"id":"1163188160","title":"长春高新表示其子公司预计将收到1.2亿美元的预付款和早期里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1163188160","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163188160?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:49","pubTimestamp":1765802949,"startTime":"0","endTime":"0","summary":"长春高新表示其子公司预计将收到1.2亿美元的预付款和早期里程碑付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0239","BK0046","BK0075","BK0057","000661","BK0028"],"gpt_icon":0},{"id":"1141150875","title":"长春高新宣布子公司与Yarrow Bioscience签署Gensci098注射剂项目许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1141150875","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141150875?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:47","pubTimestamp":1765802835,"startTime":"0","endTime":"0","summary":"长春高新宣布其子公司已与Yarrow Bioscience签署了涉及Gensci098注射剂项目的许可协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0046","000661","BK0028","BK0188","BK0239","BK0057","BK0075"],"gpt_icon":0},{"id":"2591646738","title":"长春高新最新公告:下属公司签署GenSci098注射液项目独家许可协议可至多获得13.65亿美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2591646738","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591646738?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:39","pubTimestamp":1765802387,"startTime":"0","endTime":"0","summary":"长春高新公告称,下属公司上海赛增医疗科技有限公司与Yarrow Bioscience, Inc. 签订GenSci098注射液项目独家许可协议。根据协议,赛增医疗预计可获得1.2亿美元首付款及近期开发里程碑款项,并将有资格获得与特定研发、监管及商业化有关的里程碑付款。赛增医疗将有权就本次独家许可至多获得13.65亿美元里程碑付款,后续产品上市后并有权获得超过净销售额10%的销售提成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500031815.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0057","BK0046","BK0239","91272","BK0028","BK0075","BK0188"],"gpt_icon":0},{"id":"2591614862","title":"长春高新:长效生长激素规格及医保价格说明","url":"https://stock-news.laohu8.com/highlight/detail?id=2591614862","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591614862?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:06","pubTimestamp":1765789570,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)12月15日在投资者关系平台上答复投资者关心的问题。投资者提问:金培生长激素上市了哪几个剂量规格,这次医保谈判落地价格分别是多少?公司现在说一下这个不违规吧,我们投资人想了解。长春高新回复:您好,公司长效产品主要有54IU/9.0mg/1.0ml/瓶、27IU/4.5mg/0.5ml/瓶两个规格,2026年1月1日最新版医保目录正式执行后相关价格可正式查询,具体请以国家相关部门披露为准,谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500020541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","91272","BK0075","000661","BK0188","BK0046","BK0057","BK0239"],"gpt_icon":0},{"id":"2591261106","title":"长春高新:系统性推进市值管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2591261106","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591261106?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:00","pubTimestamp":1765789253,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新12月15日在投资者关系平台上答复投资者关心的问题。请问公司是否会重新评估回购用途,考虑将部分股份用于注销以提升每股价值?公司2026年是否有明确市值管理、费用控制及提升分红或注销式回购?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500020297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","91272","BK0046","BK0057","BK0188","BK0028","BK0239","BK0075"],"gpt_icon":0},{"id":"2589337793","title":"长春高新(000661.SZ)子公司两款药品新纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589337793","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589337793?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:54","pubTimestamp":1765184075,"startTime":"0","endTime":"0","summary":"智通财经APP讯,长春高新(000661.SZ)公告,据国家医疗保障局及人力资源社会保障部发布的《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》,公司控股子公司长春金赛药业有限责任公司(简称“金赛药业”)自主研发的金赛增(现通用名为“金培生长激素注射液”)、合作引进的美适亚(通用名为“醋酸甲地孕酮口服混悬液”)均被新纳入国家医保目录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0075","000661","BK0239","BK0057","91272","BK0028","BK0046"],"gpt_icon":0},{"id":"2588919884","title":"长春高新:已回购股份将用于员工持股或股权激励","url":"https://stock-news.laohu8.com/highlight/detail?id=2588919884","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588919884?lang=zh_cn&edition=full","pubTime":"2025-12-04 20:52","pubTimestamp":1764852748,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新12月03日在投资者关系平台上答复投资者关心的问题。前几年贵司进行了一次股权激励,但后来股价倒挂没有实施。这样不仅利于有贡献的员工也利于公司的发展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400036984.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91272","BK0057","BK0075","BK0188","BK0239","BK0046","BK0028","000661"],"gpt_icon":0},{"id":"2588439800","title":"长春高新:推进多元化转型升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2588439800","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588439800?lang=zh_cn&edition=full","pubTime":"2025-12-03 19:57","pubTimestamp":1764763033,"startTime":"0","endTime":"0","summary":"自信可以但也要变通长春高新回复:感谢您对公司的关注,在合规监管越来越严格的情况下,相关适应症的拓展将使公司能够更好的适应监管要求,更有利于产品的销售;公司后续也将继续努力发挥公司品牌、渠道、质量等优势,努力推动相关产品的销售推广工作;同时,公司近年来已经在积极推进多元化转型升级,前期在生长激素研发、销售推广阶段打下的基础,也将持续赋能新管线,推进公司持续形成‘优势共享、资源复用’的良性循环,谢谢!","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300034720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","91272","BK0046","BK0057","BK0188","BK0028","BK0239","BK0075"],"gpt_icon":0},{"id":"2588043807","title":"长春高新:提升资产使用效率及项目竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2588043807","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588043807?lang=zh_cn&edition=full","pubTime":"2025-12-03 19:42","pubTimestamp":1764762127,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新12月03日在投资者关系平台上答复投资者关心的问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300034170.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91272","BK0188","BK0028","000661","BK0075","BK0046","BK0239","BK0057"],"gpt_icon":0},{"id":"2588048730","title":"长春高新:截至9月30日股东人数为104,055","url":"https://stock-news.laohu8.com/highlight/detail?id=2588048730","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588048730?lang=zh_cn&edition=full","pubTime":"2025-12-03 19:33","pubTimestamp":1764761584,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)12月03日在投资者关系平台上答复投资者关心的问题。投资者提问:你好,请问截止到今天股东人数是多少?长春高新回复:您好,截至9月30日的股东人数为104,055,对于其他期间的股东人数请持续关注定期报告等,或根据公司法及公司章程等规定进行查询,谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300033870.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000661","91272","BK0028","BK0046","BK0239","BK0057","BK0075"],"gpt_icon":0},{"id":"2586546243","title":"长春高新(000661.SZ):GenSci142胶囊境内生产药品注册临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2586546243","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586546243?lang=zh_cn&edition=full","pubTime":"2025-11-27 16:55","pubTimestamp":1764233713,"startTime":"0","endTime":"0","summary":"智通财经APP讯,长春高新(000661.SZ)公告,公司子公司长春金赛药业有限责任公司(简称“金赛药业”)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,金赛药业GenSci142胶囊注册临床试验申请获得批准。据悉,GenSci142胶囊是金赛药业开发的一款1类创新生物制品,拟用于细菌性阴道病的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0046","BK0075","000661","BK0057","91272","BK0028","BK0239"],"gpt_icon":0},{"id":"2585452675","title":"长春高新:相关工作具有不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2585452675","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585452675?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:36","pubTimestamp":1763973379,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)11月24日在投资者关系平台上答复投资者关心的问题。投资者提问:公司总经理,在今年上半年不止一次说过,下半年会有产品bd出去。 然后到了下半年又改口说到2028年可能就会有bd出去,这算不算虚假指引误导投资者?长春高新回复:公司经营管理团队积极通过多种形式推进在研管线BD等工作,但相关工作具有不确定性,后续如有达到信息披露标准的情况公司将会及时履行披露义务,具体请关注公司未来相关公告等,谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400018053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91272","BK0188","BK0028","000661","BK0075","BK0046","BK0239","BK0057"],"gpt_icon":0},{"id":"2585452884","title":"长春高新:未发现生长激素市场份额下降的科学合理性","url":"https://stock-news.laohu8.com/highlight/detail?id=2585452884","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585452884?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:30","pubTimestamp":1763973045,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)11月24日在投资者关系平台上答复投资者关心的问题。投资者提问:长效生长激素刚有一个对手上市公司就已经应对不暇。连续降价,同时市场份额也不断下降,明后两年还有至少5-7家长效要上市,届时合理推测公司生长激素业务营收将会降低到15亿以下,请问公司管理层可有应对策略?长春高新回复:公司会结合政策要求、行业及市场情况等合理制定产品价格和销售策略,另未发现您问题列示情况的科学合理性,谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400017475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","91272","BK0057","BK0028","BK0046","000661","BK0075","BK0239"],"gpt_icon":0},{"id":"2585855452","title":"长春高新:成功推出10余种新药产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2585855452","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585855452?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:27","pubTimestamp":1763972834,"startTime":"0","endTime":"0","summary":"研发成果方面,自2021年以来,公司立足于差异化创新,在内分泌及代谢疾病、女性健康、免疫及呼吸系统疾病、肿瘤、疫苗及中成药领域建立了多元化产品组合。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400017111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000661","BK0028","91272","BK0057","BK0075","BK0188","BK0046"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767023323677,"stockEarnings":[{"period":"1week","weight":-0.0168},{"period":"1month","weight":-0.0521},{"period":"3month","weight":-0.2563},{"period":"6month","weight":-0.02},{"period":"1year","weight":-0.0355},{"period":"ytd","weight":-0.0281}],"compareEarnings":[{"period":"1week","weight":0.0188},{"period":"1month","weight":0.0257},{"period":"3month","weight":0.0354},{"period":"6month","weight":0.1575},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.1826}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"长春高新技术产业(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"104055人(较上一季度减少4.63%)","perCapita":"3840股","listingDate":"1996-12-18","address":"吉林省长春市朝阳区高新区海容酒店及海茵广场写字楼B座2708室","registeredCapital":"40793万元","survey":" 长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售,辅以房地产开发等业务。公司的主要产品是注射用人生长激素、重组人生长激素注射液、聚乙二醇重组人生长激素注射液、营养保健产品、体重控制产品、电子注射笔、骨龄及生长发育检测设备、赛优姿系列产品、盐酸托莫西汀胶囊、注射用重组人促卵泡激素、醋酸曲普瑞林注射液、利丙双卡因乳膏、醋酸甲地孕酮口服混悬液、口腔凝胶。","listedPrice":8.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"长春高新,000661,长春高新股票,长春高新股票老虎,长春高新股票老虎国际,长春高新行情,长春高新股票行情,长春高新股价,长春高新股市,长春高新股票价格,长春高新股票交易,长春高新股票购买,长春高新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}